Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Clinical update on the management of atrial fibrillation.

Danelich IM, Reed BN, Hollis IB, Cook AM, Rodgers JE.

Pharmacotherapy. 2013 Apr;33(4):422-46. doi: 10.1002/phar.1217. Review.

PMID:
23553811
2.

'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.

Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP.

Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.

PMID:
24486284
3.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

4.

Treatment of atrial fibrillation.

Bajpai A, Savelieva I, Camm AJ.

Br Med Bull. 2008;88(1):75-94. doi: 10.1093/bmb/ldn046. Epub 2008 Dec 5. Review.

PMID:
19059992
5.

Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience.

Zhang J, Liu X, Liu X, Yin X, Wang Y, Lu X, Yang X.

Medicine (Baltimore). 2017 Nov;96(47):e8762. doi: 10.1097/MD.0000000000008762.

6.

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

Savelieva I, Kakouros N, Kourliouros A, Camm AJ.

Europace. 2011 Mar;13(3):308-28. doi: 10.1093/europace/eur002. Review.

PMID:
21345926
7.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
8.

Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.

Guo Y, Wang H, Tian Y, Wang Y, Lip GYH.

Chest. 2015 Jul;148(1):62-72. doi: 10.1378/chest.14-2018.

10.

Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.

Verheugt FW.

Clin Cardiol. 2013 Jun;36(6):312-22. doi: 10.1002/clc.22122. Epub 2013 Apr 8. Review.

11.

Statins and polyunsaturated fatty acids for treatment of atrial fibrillation.

Savelieva I, Camm J.

Nat Clin Pract Cardiovasc Med. 2008 Jan;5(1):30-41. Review.

PMID:
18094671
12.

Role of new drugs for management of atrial fibrillation.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM.

Ann Pharmacother. 2012 Dec;46(12):1656-70. doi: 10.1345/aph.1R155. Epub 2012 Dec 18. Review.

PMID:
23249869
13.

Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations.

Naccarelli GV, Curtis AB.

J Cardiovasc Pharmacol Ther. 2010 Sep;15(3):244-56. doi: 10.1177/1074248410370964. Epub 2010 Jun 18. Review.

PMID:
20562374
14.

Update on atrial fibrillation: part I.

Savelieva I, Camm J.

Clin Cardiol. 2008 Feb;31(2):55-62. doi: 10.1002/clc.20138. Review.

15.

Adjuvant therapy for atrial fibrillation.

Mohammed KS, Kowey PR, Musco S.

Future Cardiol. 2010 Jan;6(1):67-81. doi: 10.2217/fca.09.57. Review.

PMID:
20014988
16.

Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?

Guo Y, Pisters R, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.

Int J Cardiol. 2013 Sep 20;168(1):515-22. doi: 10.1016/j.ijcard.2012.09.187. Epub 2012 Oct 23.

PMID:
23103146
17.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
18.

Atrial fibrillation and heart failure: natural history and pharmacological treatment.

Savelieva I, John Camm A.

Europace. 2004 Sep;5 Suppl 1:S5-19. Review.

PMID:
15450275
19.

Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.

Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14.

20.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

[No authors listed]

Arch Intern Med. 1994 Jul 11;154(13):1449-57. Erratum in: Arch Intern Med 1994 Oct 10;154(19):2254.

PMID:
8018000

Supplemental Content

Support Center